Usefulness of oxidative stress marker evaluation at admission to the intensive care unit in patients with COVID-19.
Catalase
coronavirus disease 2019
critical care
discharge status
myeloperoxidase deficiency
oxidative stress
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
29
7
2021
Statut:
ppublish
Résumé
Two critical processes in the coronavirus disease 2019 (COVID-19) pandemic involve assessing patients' intensive care needs and predicting disease progression during patients' intensive care unit (ICU) stay. We aimed to evaluate oxidative stress marker status at ICU admission and ICU discharge status in patients with COVID-19. We included patients in a tertiary referral center ICU during June-December 2020. Scores of Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), and clinical severity, radiologic scores, and healthy discharge status were noted. We collected peripheral blood samples at ICU admission to evaluate total antioxidants, total oxidants, catalase, and myeloperoxidase levels. Thirty-one (24 male, 7 female) patients were included. At ICU admission, patients' mean APACHE II score at ICU admission was 17.61 ± 8.9; the mean SOFA score was 6.29 ± 3.16. There was no significant relationship between clinical severity and oxidative stress (OS) markers nor between radiological imaging and COVID-19 data classification and OS levels. Differences in OS levels between patients with healthy and exitus discharge status were not significant. We found no significant relationship between oxidative stress marker status in patients with COVID-19 at ICU admission and patients' ICU discharge status.
Identifiants
pubmed: 34310245
doi: 10.1177/03000605211027733
pmc: PMC8320569
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3000605211027733Références
Gastroenterology. 1984 Dec;87(6):1344-50
pubmed: 6092199
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Curr Biol. 2014 May 19;24(10):R453-62
pubmed: 24845678
J Clin Immunol. 2006 Nov;26(6):546-54
pubmed: 17024565
Int J Biol Sci. 2021 Jan 1;17(1):62-72
pubmed: 33390833
SAGE Open Med. 2021 Feb 1;9:2050312121991246
pubmed: 33614035
Med Hypotheses. 2020 Oct;143:110102
pubmed: 32721799
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Antioxidants (Basel). 2021 Feb 10;10(2):
pubmed: 33578849
Protein J. 2020 Dec;39(6):644-656
pubmed: 33106987
Clin Biochem. 2017 May;50(7-8):414-417
pubmed: 28167245
Exp Biol Med (Maywood). 2015 Jun;240(6):711-7
pubmed: 25888647
Antioxidants (Basel). 2020 Jul 16;9(7):
pubmed: 32708578
Clin Biochem. 2004 Feb;37(2):112-9
pubmed: 14725941
J Comp Pathol. 2014 Jul;151(1):83-112
pubmed: 24581932
Int J Infect Dis. 2020 Aug;97:303-305
pubmed: 32497811
Biochemistry (Mosc). 2020 Dec;85(12):1543-1553
pubmed: 33705292
J Pharmacogenomics Pharmacoproteomics. 2014 Sep 30;5(4):
pubmed: 25584194
Clin Biochem. 2005 Dec;38(12):1103-11
pubmed: 16214125
Eur Radiol. 2020 Sep;30(9):4930-4942
pubmed: 32346790
Crit Care. 2020 Apr 7;24(1):136
pubmed: 32264922
ACS Infect Dis. 2020 Jul 10;6(7):1558-1562
pubmed: 32463221
Methods Enzymol. 1984;105:121-6
pubmed: 6727660